Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828712 | 0.91 | — | — | |
| SCHEMBL916684 | 0.91 | SSTR5 (0.34) | SSTR5 | |
| SCHEMBL917812 | 0.91 | — | — | |
| SCHEMBL916371 | 0.90 | MAP3K12 (0.31) | — | |
| SCHEMBL917073 | 0.90 | GRIN1 (0.30) | — | |
| SCHEMBL3547325 | 0.90 | GRM2 (0.32) | SSTR5 | |
| SCHEMBL917074 | 0.89 | FFAR1 (0.32) | — | |
| SCHEMBL917566 | 0.89 | SCN10A (0.34) | — | |
| SCHEMBL12904303 | 0.87 | PDE4B (0.37) | SSTR5CHRNB4CHRNA3 | |
| SCHEMBL4983896 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED | 2011-01-27 | — | — | US | claimed |
| EP-2086948-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | Ranbaxy Laboratories Limited (IN) | 2009-08-12 | — | — | EP | claimed |
| WO-2008035315-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-27 | — | — | WO | claimed |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED | 2011-01-27 | — | — | US | disclosed |
| EP-2086948-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | Ranbaxy Laboratories Limited (IN) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008035315-A9 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LAB LTD (IN) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008035315-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | PDE4A, PDE4B, PDE4C | SSTR5 3863/4885CHRNB4 91/4885CHRNA3 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.